Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors

Archives of Gynecology and Obstetrics

Volumn 284, Issue 2, 2011, Pages 483-490

  Ünver, Nurcan Uluskan ^a   Acikalin, Mustafa Fuat ^a   Öner, Ülkü ^a   Ciftci, Evrim ^a   Ozalp, S Sinan ^a   Colak, Ertugrul ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Differential diagnosis; Immunohistochemistry; P16; P21; Uterine smooth muscle tumors

Indexed keywords

PARAFFIN; PROTEIN P16; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN UTERUS TUMOR; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR RECURRENCE; UTERUS CANCER; UTERUS MYOMA;

ADULT; AGED; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEIOMYOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SMOOTH MUSCLE TUMOR; UTERINE NEOPLASMS;

EID: 80052311933     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1690-z     Document Type: Article

References (27)

1. Zaloudek C, Hendrickson MR (2002) Mesenchymal tumors of the uterus. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract, fifth edn. Springer, New York, pp 561-615
2. Bodner-Adler B, Bodner K, Czerwenka K, Kimberger O, Leodolter S, Mayerhofer K (2005) Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 96:62-66 (Pubitemid 39612418)
3. O'Neill CJ, McBrie HA, Connolly LE, McCluggage WG (2007) Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 50:851-858 (Pubitemid 46850073)
4. Atkins KA, Arronte N, Darus CJ, Rice LW (2008) The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 32:98-102
5. Chen L, Yang B (2008) Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 27:326-332
6. Gannon BR, Manduch M, Childs TJ (2008) Differential immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Int J Gynecol Pathol 27:68-73 (Pubitemid 351627976)
7. Ip PP, Cheung AN, Clement PB (2009) Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol 33:992-1005
8. Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB (2009) A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol 22:1519-1531
9. D'Angelo E, Spagnoli LG, Prat J (2009) Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 40:1571-1585
10. Palazzo JP, Mercer WE, Kovatich AJ, McHugh M (1997) Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 28:60-66 (Pubitemid 27044483)
11. Leiser AL, Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi DS, Soslow RA (2006) Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol 101:86-91
12. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C (1984) Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33:37-42 (Pubitemid 14223231)
13. FIGO staging for uterine sarcomas (2009) Int J Gynaecol Obstet 104:179
14. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y (1994) Frequent somatic mutation of the MTS/CDK41 gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397
15. Caldas C, Hahn SA, DaCosta LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32 (Pubitemid 24274057)
16. Cohen JA, Geradts J (1997) Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. Hum Pathol 28:893-898 (Pubitemid 27355548)
17. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T, Miyajima K, Iwamoto Y, Tsuneyoshi M (2003) Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 201:487-495 (Pubitemid 37408271)
18. Qiao X, Bhuiya TA, Spitzer M (2005) Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E and p16 immunohistochemical analysis. J Low Genit Tract Dis 9:100-107 (Pubitemid 40464079)
19. Regauer S, Reich O (2007) CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from highgrade cervical intraepitheial neoplasia (CIN III). Histopathology 50:629-635 (Pubitemid 46495822)
20. Cameron RI, Maxwell P, Jenkins D, McCluggage WG (2002) Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 41:313-321 (Pubitemid 35279028)
21. Ip PP, Tse KY, Tam KF (2010) Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol 17:91-112
22. Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D (2003) ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorilation of p34Cdc2: poor responsiveness to chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer 98:1123-1130 (Pubitemid 37099896)
23. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP (2004) P53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22:1014-1024 (Pubitemid 41095033)
24. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA, Zhang W (1995) Increased levels of p21WAF1/CIP1 in human brain tumors. Oncogene 11:2021-2028 (Pubitemid 3000314)
25. Dobashi Y, Noguchi T, Nasuno S, Katayama K, Kameya T (2001) CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue. Int J Cancer 94:353-362 (Pubitemid 32906065)
26. El-Ghobashy AA, Shaaban AM, Innes J, Prime W, Herrington CS (2007) Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. Eur J Cancer 43:2011-2018 (Pubitemid 47284870)
27. Huang LW, Chou YY, Chao SL, Chen TJ, Lee TT (2001) p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol 83:348-354 (Pubitemid 33033078)